Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

@article{Kobayashi2004SafetyAP,
  title={Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors},
  author={H. Kobayashi and S. Gail Eckhardt and Jennifer A. Lockridge and M. Rothenberg and A. Sandler and C. O'bryant and W. Cooper and S. Holden and R. Aitchison and N. Usman and M. Wolin and M. Basche},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={56},
  pages={329-336}
}
PurposeRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. [...] Key MethodMethodsThe study used a sequential treatment design evaluating a single dose level for all three drugs: paclitaxel 175 mg m−2 and carboplatin AUC=6 on day 1 of a 21-day cycle, and RPI.4610 100 mg m−2 day−1 beginning on day 8 and continuing daily thereafter.Expand
Angiogenesis inhibitors in lung cancer: a promise fulfilled.
New agents for treatment of advanced transitional cell carcinoma.
  • F. Perabo, S. Müller
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
  • J. Homsi, A. Daud
  • Medicine
  • Cancer control : journal of the Moffitt Cancer Center
  • 2007
Nucleic acids as therapeutic agents.
Advanced bladder cancer: new agents and new approaches. A review.
...
1
2
3
4
...

References

SHOWING 1-10 OF 22 REFERENCES
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
  • A. Adjei, G. Dy, +11 authors F. A. Dorr
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
  • C. Rudin, M. Kozloff, +5 authors E. Vokes
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
  • K. Margolin, M. Gordon, +6 authors J. Breed
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models
Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
  • P. Pavco, K. Bouhana, +11 authors T. Parry
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
...
1
2
3
...